F8 and hemophilia A: Hemophilia A patients require a continuous supply of active FVIII protein; therefore, for gene-therapy applications, it is preferable to achieve stable and sustained expression of FVIII in order to achieve consistent therapeutic outcomes and reduce the risk of developing inhibitory antibodies.